http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 Albany, NY (June 12, 2008) - AMRI (NASDAQ: AMRI) announced today it will receive a $4 million milestone payment from Bristol-Myers Squibb Company (NYSE: BMY) as a result of Bristol-Myers Squibb's... http://pharmalicensing.com/redirs/news_rss//public/news/view/425919/2 http://pharmalicensing.com/redirs/news_rss//public/news/view/425919/2 June 11, 2008- LONDON Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced that it has obtained regulatory approval... http://pharmalicensing.com/redirs/news_rss//public/news/view/425753/2 http://pharmalicensing.com/redirs/news_rss//public/news/view/425753/2 SOUTH SAN FRANCISCO, Calif., June 16, 2008 -- Exelixis, Inc. (Nasdaq: EXEL) announced today that the company and the U.S. Food and Drug Administration (FDA) have reached agreement on the phase 3... http://pharmalicensing.com/redirs/news_rss//public/news/view/426659/2 http://pharmalicensing.com/redirs/news_rss//public/news/view/426659/2 SAN DIEGO, June 5, 2008 -- In an editorial commentary(1) in the current issue of The Journal of Infectious Diseases (JID), independent experts on cytomegalovirus (CMV) said the vaccine under... http://pharmalicensing.com/redirs/news_rss//public/news/view/424323/2 http://pharmalicensing.com/redirs/news_rss//public/news/view/424323/2 WALTHAM, MA - June 12, 2008 - Repligen Corporation (NASDAQ: RGEN) today announced that based on feedback from the Food and Drug Administration, the Company plans to initiate a Phase 2b clinical trial... http://pharmalicensing.com/redirs/news_rss//public/news/view/425856/2 http://pharmalicensing.com/redirs/news_rss//public/news/view/425856/2